VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic
Status: | Completed |
---|---|
Conditions: | Gastrointestinal, Podiatry, Diabetes |
Therapuetic Areas: | Endocrinology, Gastroenterology, Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 18 - 85 |
Updated: | 12/6/2018 |
Start Date: | October 1, 2011 |
End Date: | April 4, 2018 |
A Comparative Efficacy Study: Treatments of Non-Healing Diabetic Foot Ulcers
The primary objective of this study is to assess the effectiveness of cellular dermal
replacement tissue vs. non-viable extracellular matrix (ECM) for the treatment of non-healing
diabetic foot ulcers. Our hypothesis is that these devices are of equal efficacy.
replacement tissue vs. non-viable extracellular matrix (ECM) for the treatment of non-healing
diabetic foot ulcers. Our hypothesis is that these devices are of equal efficacy.
Inclusion Criteria:
(Answering NO will exclude patient):
- An Institutional Review Board (IRB) Informed Consent Form signed and dated prior to
any study-related activities.
- The area of the study ulcer after debridement is between 1 cm2 and 25 cm2 at Visit
3/Week 0.
- Subjects between 18 and 85 years of age.
- Subject's highest Ankle-Brachial Pressure Index (ABPI) / Ankle-Arm Index (AAI) is
greater than or equal to 0.80 and lower than 1.4 (the highest ABPI/AAI value from
three measurements within last 6 months shall apply).or a toe-arm index is equal to or
higher than 0.6.
- The patient has one or more diabetic ulcers on the target foot with only one ulcer
selected as the study (target) ulcer. The target ulcer must be at least 4 cm from a
non-target ulcer and in the Investigator's opinion, be unlikely to coalesce with
another ulcer within 12 weeks of randomization.
- Subject's study ulcer is full thickness and does not extend to bone, muscle, or
tendon.
- Subject's study ulcer has been present at least 4 weeks prior to the initial screening
(Visit 1) or 6 weeks at randomization (Visit 3).
- Subject has been diagnosed with Type 1 or Type 2 diabetes and HbA1c is less than 10%.
- Study ulcer has no clinical feature of infection (2 signs of inflammation and elevated
bacterial load of the wound).
- For female subjects of childbearing age potential, the subject has a negative
pregnancy test and is not lactating for the duration of the study.
- Subject understands the requirements of this study and is willing to comply with all
the study requirements.
Exclusion Criteria:
(Answering YES will exclude patient):
- The subject is diagnosed with cancer and is undergoing treatment with
immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids
less than 30 days before enrollment.
- The subject is diagnosed with HIV/AIDS.
- The subject is diagnosed with any bleeding disorders.
- The subject is diagnosed with any connective tissue diseases.
- For female subjects, the subject is pregnant or lactating.
- The subject has a history of illicit drug use within one year of enrollment.
- In the past year, the subject experiences episodes of drinking more than 5 alcoholic
beverages in less than two hours and/or drinking alcohol has become a problem in
interpersonal relationships, work, driving and/or their behavior in general.
- The subject has any active infected wounds or osteomyelitis (confirmed by bone biopsy,
MRI or bone scan).
- Doppler exam within the last 365 days demonstrating reflux greater than 0.5 seconds.
- The subject is diagnosed with active Charcot as described by Saunder's classification
system.
- The subject manifests signs of poor nutritional status and/or albumin level < 2.9.
- The subject has been exposed to Dermagraft and/or Oasis in the last 60 days.
- The study ulcer size is less than 0.5 cm2 or greater than 25 cm2.
- The subject has any porcine allergy or cow product allergy.
- The subject's recent (last 30 days) chemistry tests serum creatinine is 2 times above
the upper limit of normal and/or LFT's 3 times above the upper limit of normal.
- Between Visit 1/Week -2 and Visit 3/Week 0 (randomization) the study ulcer has
decreased in size by more than 40%, or increased in size by more than 50%.
We found this trial at
1
site
Click here to add this to my saved trials